SRR35579839
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.520
- MYC_TARGETS_V2+0.500
- G2M_CHECKPOINT+0.470
- MYC_TARGETS_V1+0.390
- ESTROGEN_RESPONSE_LATE+0.340
- MITOTIC_SPINDLE+0.320
- ESTROGEN_RESPONSE_EARLY+0.290
- DNA_REPAIR+0.240
- ADIPOGENESIS+0.220
- OXIDATIVE_PHOSPHORYLATION+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.610
- INTERFERON_GAMMA_RESPONSE-0.560
- IL6_JAK_STAT3_SIGNALING-0.490
- ALLOGRAFT_REJECTION-0.460
- INFLAMMATORY_RESPONSE-0.350
- COMPLEMENT-0.320
- KRAS_SIGNALING_UP-0.320
- TGF_BETA_SIGNALING-0.310
- TNFA_SIGNALING_VIA_NFKB-0.290
- IL2_STAT5_SIGNALING-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | X97abcebb.f885.4eca.9af4.91a0adb97578 | — | cohortMD1 | 0.892 |
| 2 | TCGA-EW-A2FW-01A-11R-A17B-07 | — | B | 0.888 |
| 3 | TCGA-AO-A0J7-01A-11R-A034-07 | — | B | 0.878 |
| 4 | SRR5088851 | — | — | 0.857 |
| 5 | BS_MDBT7S5Z | high-grade glioma | — | 0.856 |
| 6 | TCGA-EW-A6SA-01A-21R-A32P-07 | — | B | 0.853 |
| 7 | MBCProject_0343_T2_RNA | — | B | 0.852 |
| 8 | TCGA-77-8154-01A-11R-2247-07 | — | cohortSQ1 | 0.849 |
| 9 | SRR6013540 | — | cohortSQ2 | 0.848 |
| 10 | X299bbf8b.babb.4be2.a190.5411dc005aae | — | cohortA1 | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.340 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.290 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.130 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.090 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |